|
Characteristics
|
Values (n = 66 patients)
|
|---|
|
Age at diagnosis (years)
|
|
Median, range
|
51.5, 30–91
|
|
Stage
|
|
I
|
13 (19.7%)
|
|
II
|
39 (59.1%)
|
|
III
|
12 (18.2%)
|
|
Undetermined
|
2 (3.0%)
|
|
BRCA germline status (Sanger sequencing confirmed)
|
|
BRCA1 carrier
|
5 (7.6%)
|
|
BRCA2 carrier
|
2 (3.0%)
|
|
BRCA-negative
|
59 (89.4%)
|
|
Progression status
|
|
PFS
|
53 (80.3%)
|
|
Relapse/metastasis
|
6 (9.1%)
|
|
Death
|
1 (1.5%)
|
|
Undetermined
|
6 (9.1%)
|
|
Whether (or not) treated with neoadjuvant therapy
|
|
Yes
|
7 (10.6%)
|
|
No
|
55 (83.3%)
|
|
Undetermined
|
4 (6.1%)
|
|
Chemotherapy regimen
|
|
TEC
|
16 (24.2%)
|
|
EC-T
|
20 (30.3%)
|
|
TC
|
3 (4.5%)
|
|
Other
|
10 (15.2%)
|
|
None
|
17 (25.8%)
|
- Abbreviations: PFS progression-free survival, TEC docetaxel-epirubicin-cyclophosphamide, EC-T epirubicin-cyclophosphamide followed by docetaxel, TC docetaxel-cyclophosphamide
